, WHO. World Health Organisation, 2018.

D. A. Solomon, M. B. Keller, A. C. Leon, T. I. Mueller, P. W. Lavori et al., Multiple recurrences of major depressive disorder, Am J Psychiatry, vol.157, issue.2, pp.229-233, 2000.

R. C. Kessler and E. J. Bromet, The epidemiology of depression across cultures, Annu Rev Public Health, vol.34, pp.119-138, 2013.

M. M. Weissman, R. C. Bland, G. J. Canino, C. Faravelli, S. Greenwald et al., Cross-national epidemiology of major depression and bipolar disorder, JAMA, vol.276, issue.4, pp.293-299, 1996.

S. Van-de-velde, P. Bracke, and K. Levecque, Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression, Soc Sci Med, vol.71, pp.305-313, 2010.

S. M. Bentley, G. L. Pagalilauan, and S. A. Simpson, Major depression, Med Clin North Am, vol.98, issue.5, pp.981-1005, 2014.

D. Bodinat, C. Guardiola-lemaitre, B. Mocaër, E. , R. P. Muñoz et al., Agomelatine, the first melatonergic antidepressant: discovery, characterization and development, Nat Rev Drug Discov, vol.9, issue.8, p.628, 2010.

G. Racagni, M. A. Riva, R. Molteni, L. Musazzi, F. Calabrese et al., Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors, World J Biol Psychiatry, vol.12, issue.8, pp.574-587, 2011.

A. Cipriani, T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, vol.391, pp.1357-1366, 2018.

D. Taylor, A. Sparshatt, S. Varma, and O. Olofinjana, Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies, Br Med J, vol.348, p.1888, 2014.

A. Khan, M. Detke, S. R. Khan, and C. Mallinckrodt, Placebo response and antidepressant clinical trial outcome, J Nerv Ment Dis, vol.191, issue.4, pp.211-218, 2003.

N. Iovieno and G. I. Papakostas, Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis, J Clin Psychiatry, vol.73, issue.10, pp.1300-1306, 2012.

M. Hamilton, A rating scale for depression, J Neurol Neurosurg Psychiatry, vol.23, issue.1, pp.56-62, 1960.

D. Faries, J. Herrera, J. Rayamajhi, D. Debrota, M. Demitrack et al., The responsiveness of the Hamilton depression rating scale, J Psychiatr Res, vol.34, issue.1, pp.3-10, 2000.

R. M. Bagby, A. G. Ryder, D. R. Schuller, and M. B. Marshall, The Hamilton Depression Rating Scale: has the gold standard become a lead weight?, Am J Psychiatry, vol.161, issue.12, pp.2163-2177, 2004.

P. Bech and O. Rafaelsen, The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale, Acta Psychiatr Scand, vol.62, issue.S285, pp.128-132, 1980.

R. D. Gibbons, D. C. Clark, and D. J. Kupfer, Exactly what does the Hamilton depression rating scale measure?, J Psychiatr Res, vol.27, issue.3, pp.259-273, 1993.

S. A. Montgomery and M. Åsberg, A new depression scale designed to be sensitive to change, Br J Psychiatry, vol.134, issue.4, pp.382-389, 1979.

W. Maier and M. Philipp, Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale, Pharmacopsychiatry, vol.18, issue.01, pp.114-115, 1985.

R. Mcintyre, S. Kennedy, R. M. Bagby, and D. Bakish, Assessing full remission, J Psychiatry Neurosci, vol.27, issue.4, p.235, 2002.

S. Ueckert, E. L. Plan, K. Ito, M. O. Karlsson, B. Corrigan et al., Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling, Pharm Res, vol.31, issue.8, pp.2152-2165, 2014.

S. Buatois, S. Retout, N. Frey, and S. Ueckert, Item response theory as an efficient tool to describe a heterogeneous clinical rating scale in de novo idiopathic Parkinson's disease patients, Pharm Res, vol.34, issue.10, pp.2109-2118, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01563224

R. D. Bock, A brief history of item theory response, J Educ Meas, vol.16, issue.4, pp.21-33, 1997.

N. Verma, S. N. Beretvas, B. Pascual, J. C. Masdeu, and M. K. Markey, New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials, Alzheimer's Res Ther, vol.7, issue.1, p.64, 2015.

L. S. Schneider, R. E. Kennedy, G. Wang, and G. R. Cutter, Differences in Alzheimer disease clinical trial outcomes based on age of the participants, Neurology, vol.84, issue.11, pp.1121-1127, 2015.

N. M. Dowling, D. M. Bolt, and S. Deng, An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Psychol Assess, vol.28, issue.12, p.1576, 2016.

A. M. Novakovic, E. H. Krekels, A. Munafo, S. Ueckert, and M. O. Karlsson, Application of item response theory to modeling of expanded disability status scale in multiple sclerosis, AAPS J, vol.19, issue.1, pp.172-179, 2017.

M. Vandemeulebroecke, B. Bornkamp, T. Krahnke, J. Mielke, A. Monsch et al., A longitudinal item response theory model to characterize cognition over time in elderly subjects, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.9, pp.635-641, 2017.

P. Välitalo, E. Krekels, M. Van-dijk, S. Simons, D. Tibboel et al., Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.4, pp.239-248, 2017.

G. Gottipati, M. O. Karlsson, and E. L. Plan, Modeling a Composite Score in Parkinson's Disease Using Item Response Theory, AAPS J, vol.19, issue.3, pp.837-845, 2017.

E. Krekels, A. M. Novakovic, A. Vermeulen, L. E. Friberg, and K. Mo, Item response theory to quantify longitudinal placebo and paliperidone effects on PANSS scores in schizophrenia, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.8, pp.543-551, 2017.

J. Guk, C. D. Son, H. Yoo, J. Heo, J. H. Park et al., Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke, Br J Clin Pharmacol, vol.84, issue.11, pp.2586-2599, 2018.

D. Chae and K. Park, An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients, J Pharmacokinet Pharmacodyn, vol.45, issue.5, pp.721-731, 2018.

F. B. Baker, The basics of item response theory. ERIC, 2001.

R. Gomeni, A. Lavergne, and E. Merlo-pich, Modelling placebo response in depression trials using a longitudinal model with informative dropout, Eur J Pharm Sci, vol.36, issue.1, pp.4-10, 2009.

G. M. Goodwin, R. Emsley, S. Rembry, and F. Rouillon, Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, vol.70, issue.8, pp.1128-1137, 2009.

J. L. Claghorn and J. P. Feighner, A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression, J Clin Psychopharmacol, 1993.

D. D. Mitsikostas, L. Mantonakis, and N. Chalarakis, Nocebo in clinical trials for depression: a meta-analysis, Psychiatry Res, vol.215, issue.1, pp.82-86, 2014.

S. Mazumdar, G. Tang, P. R. Houck, M. A. Dew, A. E. Begley et al., Statistical Analysis of Longitudinal Psychiatric Data with Dropouts, J Psychiatr Res, vol.41, issue.12, pp.1032-1041, 2007.

R. J. Little, Modeling the drop-out mechanism in repeated-measures studies, J Am Stat Assoc, vol.90, issue.431, pp.1112-1121, 1995.

C. Hu and M. E. Sale, A joint model for nonlinear longitudinal data with informative dropout, J Pharmacokinet Pharmacodyn, vol.30, issue.1, pp.83-103, 2003.

M. A. Björnsson, L. E. Friberg, and U. S. Simonsson, Performance of nonlinear mixed effects models in the presence of informative dropout, AAPS J, vol.17, issue.1, pp.245-255, 2015.

P. Olié, J. Kasper, and S. , Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, Int J Neuropsychopharmacol, vol.10, issue.5, pp.661-673, 2007.

S. Kennedy and R. Emsley, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur Neuropsychopharmacol, vol.16, issue.2, pp.93-100, 2006.

S. H. Kennedy, A. Avedisova, N. Giménez-montesinos, and C. Belaïdi, A placebocontrolled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder, Eur Neuropsychopharmacol, vol.24, issue.4, pp.553-563, 2014.

R. Heun, A. Ahokas, P. Boyer, N. Giménez-montesinos, F. Pontes-soares et al., The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study, J Clin Psychiatry, vol.74, issue.6, pp.587-94, 2013.

P. Jacqmin, E. Snoeck, E. Van-schaick, R. Gieschke, P. Pillai et al., Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model, J Pharmacokinet Pharmacodyn, vol.34, issue.1, pp.57-85, 2007.

J. Cohen, Statistical power analysis for the behavioral sciences 2nd edn, Erlbaum Associates, 1988.

M. C. Kjellsson, P. H. Zingmark, E. N. Jonsson, and M. O. Karlsson, Comparison of proportional and differential odds models for mixed-effects analysis of categorical data, J Pharmacokinet Pharmacodyn, vol.35, issue.5, p.483, 2008.

S. Ueckert, Modeling composite assessment data using item response theory, CPT Pharmacometrics Syst Pharmacol, vol.7, issue.4, pp.205-218, 2018.

R. Gomeni and E. Merlo-pich, Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials, Br J Clin Pharmacol, vol.63, issue.5, pp.595-613, 2007.

N. Holford, J. Li, L. Benincosa, and M. Birath, Population disease progress models for the time course of HAMD score in depressed patients receiving placebo in anti-depressant clinical trials. Abstracts of the XI annual meeting of the population approach group in Europe, 2002.

D. R. Mould, Pharmacometrics: the science of quantitative pharmacology, pp.547-581, 2007.

E. Y. Shang, M. A. Gibbs, J. W. Landen, M. Krams, T. Russell et al., Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder, J Pharmacokinet Pharmacodyn, vol.36, issue.1, pp.63-80, 2009.

J. R. Bauer and . Icon-s-development, NONMEM users guide: Introduction to NONMEM 7.3.0, 2013.

A. Russu, E. Marostica, D. Nicolao, G. Hooker, A. C. Poggesi et al., Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression, Clin Pharmacol Ther, vol.91, issue.5, pp.863-871, 2012.

M. Papp, P. Gruca, P. A. Boyer, and E. Mocaër, Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat, Neuropsychopharmacology, vol.28, issue.4, p.694, 2003.

S. P. Singh, V. Singh, and N. Kar, Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal, Int J Neuropsychopharmacol, vol.15, issue.3, pp.417-428, 2012.

M. Koesters, G. Guaiana, A. Cipriani, T. Becker, and C. Barbui, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, Br J Psychiatry, vol.203, issue.3, pp.179-187, 2013.

C. Cusin, H. Yang, A. Yeung, and M. Fava, Handbook of clinical rating scales and assessment in psychiatry and mental health, pp.7-35, 2009.

N. Holford and K. E. Peace, Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine, Proc Natl Acad Sci, vol.89, issue.23, pp.11466-11470, 1992.

M. Zimmerman, J. H. Martinez, D. Young, I. Chelminski, and K. Dalrymple, Severity classification on the Hamilton depression rating scale, J Affect Disord, vol.150, issue.2, pp.384-388, 2013.

. R-core-team, R: A Language and Environment for Statistical Computing, 2018.

M. Lavielle and . Mlxr, Simulation of Longitudinal Data, 2018.